Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of JX2201 in adults with elevated lipoprotein(a) at high cardiovascular risk
CTR20260871Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JX2201 in lipoprotein(a) hyperlipoproteinemia (Lp(a)), dyslipidemia, sponsored by Hengrui Therapeutics. Started Mar 2026; status: active.
02
Drugs
JX2201
03
Conditions
lipoprotein(a) hyperlipoproteinemia (Lp(a))dyslipidemia
Beyond the preview
Go deeper on CTR20260871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260871.